Third quarter 2022 results

Third quarter 2022 results were reviewed by management during a live audio webcast with the financial community. The presentation was followed by a Q&A session.

Featuring

Paul Hudson

Paul Hudson

Chief Executive Officer

Jean-Baptiste de Chatillon

Jean-Baptiste de Chatillon

Chief Financial Officer

Bill Sibold

Bill Sibold

Specialty Care

Olivier Charmeil

Olivier Charmeil

General Medicines

John Reed

John Reed

R&D

Thomas Triomphe

Thomas Triomphe

Vaccines

Julie Van Ongevalle

Julie Van Ongevalle

Consumer Healthcare

Roy Papatheodorou

Roy Papatheodorou

General Counsel

Highlights

 

 

“Our exceptional results for the third quarter demonstrate that Sanofi is on the right path. We delivered remarkable sales growth and our commitment to breakthrough science is bearing fruit as we achieved key regulatory milestones for three of our priority medicines.”
Paul Hudson

Paul Hudson

Chief Executive Officer, Sanofi

Downloads

Press release

Presentation

Q3 2022 Income statements

Q3 2022 net sales by GBU, franchise, geographic region and product

R&D appendix

Download infographic

Q3 2022 Memorandum for modelling purposes

Contact

Investor Relations
investor.relations (at) sanofi.com 

More contact information